Hepatitis C treatment to be provided to children by NHS

24 August 2021

Children in England are set to be the first in the world to be offered direct acting antiviral (DAA) tablets for hepatitis C, as part of National Health Service (NHS) plans to eradicate the disease entirely.

More than 100 children have been identified for treatment, with hundreds more set to benefit in the coming months and years. Those aged three to 18 years will be given the tablets to treat and cure the condition.

Patients are treated with five antiviral tablets, with two follow-up blood tests – one at the end of their treatment and another 24 weeks later and, if both are negative, it means the child has been cured of hepatitis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK